tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DE:SNW Stock Latest News

Sanofi’s Innovative Approach in Type 1 Diabetes Treatment: A Clinical Study Update
Company AnnouncementsSanofi’s Innovative Approach in Type 1 Diabetes Treatment: A Clinical Study Update
2d ago
SNY
Sanofi’s New Study on Lunsekimig for Chronic Rhinosinusitis: A Potential Game Changer?
PremiumCompany Announcements
Sanofi’s New Study on Lunsekimig for Chronic Rhinosinusitis: A Potential Game Changer?
2d ago
SNY
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment
2d ago
SNY
REGN
Sanofi’s Phase 3 Study on Amlitelimab for Atopic Dermatitis: A Potential Game-Changer?
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Amlitelimab for Atopic Dermatitis: A Potential Game-Changer?
2d ago
SNY
Regeneron and Sanofi’s AROMA Study: Long-Term Insights on DUPIXENT® for CRSwNP
PremiumCompany Announcements
Regeneron and Sanofi’s AROMA Study: Long-Term Insights on DUPIXENT® for CRSwNP
2d ago
SNY
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis
PremiumCompany AnnouncementsRegeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis
3d ago
SNY
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game Changer for Chronic Rhinosinusitis
Premium
Company Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game Changer for Chronic Rhinosinusitis
3d ago
SNY
REGN
Sanofi’s Promising Ulcerative Colitis Study: A Potential Game-Changer?
Premium
Company Announcements
Sanofi’s Promising Ulcerative Colitis Study: A Potential Game-Changer?
3d ago
SNY
Sanofi’s Promising Crohn’s Disease Study: A Potential Game-Changer for Investors
PremiumCompany Announcements
Sanofi’s Promising Crohn’s Disease Study: A Potential Game-Changer for Investors
3d ago
SNY
Sanofi’s Frexalimab Study: A Potential Game-Changer in Type 1 Diabetes Treatment
PremiumCompany Announcements
Sanofi’s Frexalimab Study: A Potential Game-Changer in Type 1 Diabetes Treatment
3d ago
SNY
Sanofi’s New RSV Vaccine Study: What Investors Need to Know
PremiumCompany Announcements
Sanofi’s New RSV Vaccine Study: What Investors Need to Know
3d ago
SNY
Sanofi’s Promising Phase 3 Study on Frexalimab for Multiple Sclerosis: A Potential Game Changer
PremiumCompany Announcements
Sanofi’s Promising Phase 3 Study on Frexalimab for Multiple Sclerosis: A Potential Game Changer
4d ago
SNY
Sanofi’s New Diabetes Study: A Potential Game-Changer for T1D Treatment
PremiumCompany AnnouncementsSanofi’s New Diabetes Study: A Potential Game-Changer for T1D Treatment
4d ago
SNY
Sanofi’s Latest Diabetes Study: A Potential Game-Changer for Type 2 Diabetes Treatment
Premium
Company Announcements
Sanofi’s Latest Diabetes Study: A Potential Game-Changer for Type 2 Diabetes Treatment
4d ago
SNY
Sanofi’s New Study on Lunsekimig: A Potential Game Changer for CRSwNP Treatment?
Premium
Company Announcements
Sanofi’s New Study on Lunsekimig: A Potential Game Changer for CRSwNP Treatment?
4d ago
SNY
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Eosinophilic Gastritis
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Eosinophilic Gastritis
4d ago
SNY
REGN
Thermo Fisher to acquire Sanofi steriles manufacturing site in New Jersey
PremiumThe Fly
Thermo Fisher to acquire Sanofi steriles manufacturing site in New Jersey
4d ago
SNY
TMO
Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
PremiumThe Fly
Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
4d ago
MU
AMD
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for Chronic Rhinosinusitis Treatment
5d ago
SNY
REGN
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP
PremiumCompany AnnouncementsRegeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game-Changer for CRSwNP
5d ago
SNY
REGN
Regeneron and Sanofi’s Asthma Study: A Potential Game-Changer in Treatment
Premium
Company Announcements
Regeneron and Sanofi’s Asthma Study: A Potential Game-Changer in Treatment
6d ago
SNY
REGN
Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus Treatment
Premium
Company Announcements
Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus Treatment
6d ago
SNY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >